TELEFLEX INCORPORATED (NYSE:TFX) Files An 8-K Financial Statements and ExhibitsItem 9.01 of Form 8-K. This Amendment No. 2 on Form 8-K further amends, and should be read together with, the Original 8-K and the Amendment No.1 principally to include additional pro forma financial information for the nine months ended October 1, 2017, which information was not required to be included in the Original 8-K or Amendment No. 1. The Company is providing this information so that is may be incorporated by reference in a prospectus supplement being filed today by the Company in connection with its offering of senior notes.
Item 9.01. Financial Statements and Exhibits.
(a) Pro forma financial information.
The following information is filed as Exhibit 99.1 to this Amendment No. 2 and incorporated herein by reference:
|
(i) |
Unaudited pro forma condensed combined consolidated statement of earnings for the nine months ended October 1, 2017. |
|
(ii) |
Notes to the unaudited pro forma condensed combined financial information. |
(d)Exhibits.
The following exhibits are filed with this Amendment No. 2:
|
Exhibit No. |
Description |
|
99.1 |
Unaudited pro forma condensed combined consolidated statement of earnings for nine months ended October 1, 2017, and the related notes to the unaudited pro forma condensed combined financial Information. |
TELEFLEX INC ExhibitEX-99.1 2 a991-unauditedproformacond.htm EXHIBIT 99.1 Exhibit Exhibit 99.1UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATIONThe following unaudited pro forma condensed combined statement of income and related notes present the historical results of Teleflex Incorporated (“Teleflex”) for the nine months ended October 1,…To view the full exhibit click here
About TELEFLEX INCORPORATED (NYSE:TFX)
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company markets and sells its products to hospitals and healthcare providers, across the world, through a combination of its direct sales force and distributors. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company manufactures its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. The Company’s all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.
